Cannara Biotech Net Income
| LOVFF Stock | USD 1.31 0.09 6.43% |
As of the 15th of February 2026, Cannara Biotech shows the Downside Deviation of 2.95, mean deviation of 1.82, and Risk Adjusted Performance of 0.0692. In respect to fundamental indicators, the technical analysis model gives you tools to check existing technical drivers of Cannara Biotech, as well as the relationship between them. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We were able to analyze and collect data for nineteen technical drivers for Cannara Biotech, which can be compared to its peers. Please confirm Cannara Biotech treynor ratio, as well as the relationship between the downside variance and kurtosis to decide if Cannara Biotech is priced correctly, providing market reflects its regular price of 1.31 per share. Given that Cannara Biotech is a hitting penny stock territory we recommend to closely look at its total risk alpha.
Cannara Biotech's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Cannara Biotech's valuation are provided below:Cannara Biotech does not presently have any fundamental signals for analysis. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. Cannara |
Cannara Biotech 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Cannara Biotech's otc stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Cannara Biotech.
| 11/17/2025 |
| 02/15/2026 |
If you would invest 0.00 in Cannara Biotech on November 17, 2025 and sell it all today you would earn a total of 0.00 from holding Cannara Biotech or generate 0.0% return on investment in Cannara Biotech over 90 days. Cannara Biotech is related to or competes with Grown Rogue, Shield Therapeutics, HLS Therapeutics, Orexo AB, Biosyent, Orexo AB, and Kintor Pharmaceutical. Cannara Biotech Inc., together with its subsidiaries, engages in the indoor cultivation, processing, and sale of cannabi... More
Cannara Biotech Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Cannara Biotech's otc stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Cannara Biotech upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 2.95 | |||
| Information Ratio | 0.051 | |||
| Maximum Drawdown | 13.87 | |||
| Value At Risk | (3.94) | |||
| Potential Upside | 6.56 |
Cannara Biotech Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Cannara Biotech's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Cannara Biotech's standard deviation. In reality, there are many statistical measures that can use Cannara Biotech historical prices to predict the future Cannara Biotech's volatility.| Risk Adjusted Performance | 0.0692 | |||
| Jensen Alpha | 0.2146 | |||
| Total Risk Alpha | (0) | |||
| Sortino Ratio | 0.0463 | |||
| Treynor Ratio | (0.64) |
Cannara Biotech February 15, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.0692 | |||
| Market Risk Adjusted Performance | (0.63) | |||
| Mean Deviation | 1.82 | |||
| Semi Deviation | 1.89 | |||
| Downside Deviation | 2.95 | |||
| Coefficient Of Variation | 1297.33 | |||
| Standard Deviation | 2.68 | |||
| Variance | 7.16 | |||
| Information Ratio | 0.051 | |||
| Jensen Alpha | 0.2146 | |||
| Total Risk Alpha | (0) | |||
| Sortino Ratio | 0.0463 | |||
| Treynor Ratio | (0.64) | |||
| Maximum Drawdown | 13.87 | |||
| Value At Risk | (3.94) | |||
| Potential Upside | 6.56 | |||
| Downside Variance | 8.68 | |||
| Semi Variance | 3.56 | |||
| Expected Short fall | (3.37) | |||
| Skewness | 0.5295 | |||
| Kurtosis | 1.23 |
Cannara Biotech Backtested Returns
Cannara Biotech appears to be dangerous, given 3 months investment horizon. Cannara Biotech secures Sharpe Ratio (or Efficiency) of 0.0929, which signifies that the company had a 0.0929 % return per unit of risk over the last 3 months. We have found twenty-six technical indicators for Cannara Biotech, which you can use to evaluate the volatility of the firm. Please makes use of Cannara Biotech's Downside Deviation of 2.95, risk adjusted performance of 0.0692, and Mean Deviation of 1.82 to double-check if our risk estimates are consistent with your expectations. On a scale of 0 to 100, Cannara Biotech holds a performance score of 7. The firm shows a Beta (market volatility) of -0.31, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning Cannara Biotech are expected to decrease at a much lower rate. During the bear market, Cannara Biotech is likely to outperform the market. Please check Cannara Biotech's kurtosis, price action indicator, as well as the relationship between the downside variance and treynor ratio , to make a quick decision on whether Cannara Biotech's price patterns will revert.
Auto-correlation | -0.25 |
Weak reverse predictability
Cannara Biotech has weak reverse predictability. Overlapping area represents the amount of predictability between Cannara Biotech time series from 17th of November 2025 to 1st of January 2026 and 1st of January 2026 to 15th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Cannara Biotech price movement. The serial correlation of -0.25 indicates that over 25.0% of current Cannara Biotech price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.25 | |
| Spearman Rank Test | 0.04 | |
| Residual Average | 0.0 | |
| Price Variance | 0.0 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, Cannara Biotech reported net income of 2.31 M. This is 99.32% lower than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—Specialty & Generic industry. The net income for all United States stocks is 99.6% higher than that of the company.
Cannara Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Cannara Biotech's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the otc stocks which would be a good addition to a portfolio. Peer analysis of Cannara Biotech could also be used in its relative valuation, which is a method of valuing Cannara Biotech by comparing valuation metrics of similar companies.Cannara Biotech is currently under evaluation in net income category among its peers.
Cannara Fundamentals
| Return On Equity | 0.0434 | |||
| Return On Asset | 0.0327 | |||
| Profit Margin | 0.07 % | |||
| Operating Margin | 0.15 % | |||
| Current Valuation | 94.03 M | |||
| Shares Outstanding | 877.48 M | |||
| Shares Owned By Insiders | 47.54 % | |||
| Price To Earning | 85.00 X | |||
| Price To Book | 1.37 X | |||
| Price To Sales | 1.81 X | |||
| Revenue | 35.84 M | |||
| Gross Profit | 17.33 M | |||
| EBITDA | 8.14 M | |||
| Net Income | 2.31 M | |||
| Cash And Equivalents | 3.88 M | |||
| Total Debt | 46.19 M | |||
| Debt To Equity | 0.49 % | |||
| Current Ratio | 2.13 X | |||
| Book Value Per Share | 0.08 X | |||
| Cash Flow From Operations | (6.08 M) | |||
| Earnings Per Share | 0.15 X | |||
| Beta | 1.52 | |||
| Market Capitalization | 63.27 M | |||
| Total Asset | 125.62 M | |||
| Z Score | 0.6 | |||
| Net Asset | 125.62 M |
About Cannara Biotech Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Cannara Biotech's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Cannara Biotech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Cannara Biotech based on its fundamental data. In general, a quantitative approach, as applied to this otc stock, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| FSLY | Fastly Class A | |
| MOB | Mobilicom Limited American | |
| CMG | Chipotle Mexican Grill | |
| CSAN | Cosan SA ADR | |
| RKT | Rocket Companies |
Other Information on Investing in Cannara OTC Stock
Cannara Biotech financial ratios help investors to determine whether Cannara OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Cannara with respect to the benefits of owning Cannara Biotech security.